Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Columbia Univ/ NYSPI Division on Substance Abuse
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Recreational use of prescription opioids at least once per month within the past year
- No current major mood, psychotic, or anxiety disorder
- Physically healthy
- aspartate aminotransferase (AST) or alanine aminotransferase (ALT) within normal limits
- Able to perform study procedures 6.21-45 years of age
7.Blood glucose concentration between 70-145 mg/dl for men and 70-125 mg/dl for women (fasting) 8.Hb > 13 for men and Hb > 11 for women with no other evidence of medical disorder resulting in blood loss or anemia/hematological disease
Exclusion Criteria:
- Physical dependence on any drugs, excluding nicotine and caffeine
- Participants requesting treatment
- Participants on parole or probation
- Pregnancy or lactation: Female participants must agree to the use of a barrier control method of contraception (e.g. male and female condoms, diaphragms, cervical caps and contraceptive sponges used in combination with spermicide)
- Current or recent history of significant violent behavior (within the past 6 months)
- Current major Axis I psychopathology that might interfere with ability to participate in the study
- Significant suicide risk
- Current chronic pain
- Current or history of congestive heart failure, edema, or diabetes mellitus
- Sensitivity, allergy, or contraindication to opioids or pioglitazone
- Unstable physical disorders that might make participation hazardous, such as end-stage AIDS, hypertension (blood pressure > 140/90), or heart disease (please note that participants will be asked about previous visits to a cardiologist, chest pain, or strong palpitations; if these exist, they will be referred to a cardiologist and excluded unless cleared for participation by a cardiologist)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo Maintenance Period
Participants will complete the various outcome measures following a 2-3 week maintenance period on Placebo (PCB).
|
A PPARγ agonist, also marketed as Actos.
Participants will be maintained on ascending doses of Placebo, pioglitazone 15 mg and 45 mg, prior to completing a lab session at the end of each dosing period.
Other Names:
|
|
Experimental: PIO 15 Maintenance Period
Participants will complete the various outcome measures following a 2-3 week maintenance period on Pioglitazone (PIO) 15 mg.
|
A PPARγ agonist, also marketed as Actos.
Participants will be maintained on ascending doses of Placebo, pioglitazone 15 mg and 45 mg, prior to completing a lab session at the end of each dosing period.
Other Names:
|
|
Experimental: PIO 45 Maintenance Period
Participants will complete the various outcome measures following a 2-3 week maintenance period on Pioglitazone (PIO) 45 mg.
|
A PPARγ agonist, also marketed as Actos.
Participants will be maintained on ascending doses of Placebo, pioglitazone 15 mg and 45 mg, prior to completing a lab session at the end of each dosing period.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Subjective Ratings of "Good" Drug Effect
Time Frame: Measured during the lab session conducted at the end of each maintenance period
|
Visual analog scale ratings (0-100 mm scale, 0=Not at all, 100=Extremely)
|
Measured during the lab session conducted at the end of each maintenance period
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Analgesic Responses Using the Cold Pressor Test
Time Frame: Measured during the lab session conducted at the end of each maintenance period
|
Latency to withdraw hand from cold water during the cold pressor test.
|
Measured during the lab session conducted at the end of each maintenance period
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Sandra D Comer, MD, Columbia University
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 6106
- R01DA09236 (Other Identifier: NIH Grant Award Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.